# Avadel Pharmaceuticals plc (AVDL)

Source: https://www.quantisnow.com/company/AVDL
Generated: 2026-10-30T17:21:48.463Z

- Ticker: AVDL
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: avadel.com

## About

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

## Latest AVDL news and filings

- 2026-02-23 11:01 UTC [SEC Form 15-12G filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-avadel-pharmaceuticals-plc-6405905)
- 2026-02-18 22:18 UTC [SEC Form 4] [Former 10% Owner Weiss Asset Management Lp sold $233,353,092 worth of Ordinary Shares (11,112,052 units at $21.00) (SEC Form 4)](https://www.quantisnow.com/insight/former-10-owner-weiss-asset-management-lp-sold-233353092-worth-6400331)
- 2026-02-18 22:07 UTC [SEC Form 3] [New insider Weiss Asset Management Lp claimed ownership of 11,112,052 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-weiss-asset-management-lp-claimed-ownership-of-11112052-6400215)
- 2026-02-17 21:23 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-avadel-pharmaceuticals-plc-6396365)
- 2026-02-17 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-avadel-pharmaceuticals-plc-6393930)
- 2026-02-17 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-avadel-pharmaceuticals-plc-6393927)
- 2026-02-17 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-avadel-pharmaceuticals-plc-6393920)
- 2026-02-17 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-avadel-pharmaceuticals-plc-6393913)
- 2026-02-12 22:36 UTC [SEC Form 4] [SEC Form 4 filed by Chief Operating Officer Rodriguez Susan](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-operating-officer-rodriguez-susan-6390490)
- 2026-02-12 22:36 UTC [SEC Form 4] [Director Thornton Peter J. returned $2,416,260 worth of Ordinary Shares to the company (115,060 units at $21.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-thornton-peter-j-returned-2416260-worth-of-ordinary-shares-6390487)
- 2026-02-12 22:35 UTC [SEC Form 4] [Gen. Counsel & Corp. Secretary Seurer Jerad G. returned $493,416 worth of Ordinary Shares to the company (23,496 units at $21.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/gen-counsel-corp-secretary-seurer-jerad-g-returned-493416-worth-6390486)
- 2026-02-12 22:35 UTC [SEC Form 4] [Director Palczuk Linda returned $1,657,005 worth of Ordinary Shares to the company (78,905 units at $21.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-palczuk-linda-returned-1657005-worth-of-ordinary-shares-to-6390484)
- 2026-02-12 22:34 UTC [SEC Form 4] [Chief Financial Officer Mchugh Thomas S returned $2,108,400 worth of Ordinary Shares to the company (100,400 units at $21.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-mchugh-thomas-s-returned-2108400-worth-of-6390483)
- 2026-02-12 22:33 UTC [SEC Form 4] [Director Mccamish Mark Anthony returned $1,869,525 worth of Ordinary Shares to the company (89,025 units at $21.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-mccamish-mark-anthony-returned-1869525-worth-of-ordinary-shares-6390481)
- 2026-02-12 22:33 UTC [SEC Form 4] [Director Glass Geoffrey Michael returned $3,506,664 worth of Ordinary Shares to the company (166,984 units at $21.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-glass-geoffrey-michael-returned-3506664-worth-of-ordinary-shares-6390478)
- 2026-02-12 22:32 UTC [SEC Form 4] [Director Ende Eric J returned $4,618,005 worth of Ordinary Shares to the company (219,905 units at $21.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-ende-eric-j-returned-4618005-worth-of-ordinary-shares-6390475)
- 2026-02-12 22:32 UTC [SEC Form 4] [Chief Executive Officer Divis Gregory J returned $4,643,205 worth of Ordinary Shares to the company (221,105 units at $21.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-divis-gregory-j-returned-4643205-worth-of-6390473)
- 2026-02-12 22:31 UTC [SEC Form 4] [Director Amin Naseem returned $462,000 worth of Ordinary Shares to the company (22,000 units at $21.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-amin-naseem-returned-462000-worth-of-ordinary-shares-to-6390466)
- 2026-02-12 21:59 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-avadel-pharmaceuticals-plc-6390259)
- 2026-02-12 21:58 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-avadel-pharmaceuticals-plc-6390252)
- 2026-02-12 21:58 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-avadel-pharmaceuticals-plc-6390250)
- 2026-02-12 21:57 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-avadel-pharmaceuticals-plc-6390245)
- 2026-02-12 21:56 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-avadel-pharmaceuticals-plc-6390240)
- 2026-02-12 21:56 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-avadel-pharmaceuticals-plc-6390235)
- 2026-02-12 21:55 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-avadel-pharmaceuticals-plc-6390231)
- 2026-02-12 21:50 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-avadel-pharmaceuticals-plc-6390190)
- 2026-02-12 21:43 UTC [SEC Form POS AM filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-avadel-pharmaceuticals-plc-6390133)
- 2026-02-12 21:42 UTC [SEC Form POS AM filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-avadel-pharmaceuticals-plc-6390127)
- 2026-02-12 21:42 UTC [SEC Form POS AM filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-avadel-pharmaceuticals-plc-6390116)
- 2026-02-12 21:41 UTC [SEC Form POS AM filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-avadel-pharmaceuticals-plc-6390109)
- 2026-02-12 21:38 UTC [SEC Form POSASR filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-avadel-pharmaceuticals-plc-6390082)
- 2026-02-12 14:53 UTC [SEC Form 25-NSE filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-avadel-pharmaceuticals-plc-6388757)
- 2026-02-12 12:40 UTC [SEC Form 8-K] [Avadel Pharmaceuticals plc filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure](https://www.quantisnow.com/insight/avadel-pharmaceuticals-plc-filed-sec-form-8-k-completion-of-acquisition-6388323)
- 2026-02-12 12:30 UTC [Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market](https://www.quantisnow.com/insight/alkermes-plc-completes-acquisition-of-avadel-pharmaceuticals-plc-accelerating-entry-6388278)
- 2026-02-10 21:05 UTC [Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing](https://www.quantisnow.com/insight/avadel-pharmaceuticals-announces-outcome-of-the-court-sanction-hearing-6383956)
- 2026-02-06 21:10 UTC [SEC Form 4] [Director Mccamish Mark Anthony gifted 67,025 units of Ordinary Shares and received a gift of 67,025 units of Ordinary Shares (SEC Form 4)](https://www.quantisnow.com/insight/director-mccamish-mark-anthony-gifted-67025-units-of-ordinary-shares-6379760)
- 2026-01-20 11:02 UTC [SEC Form 8-K] [Avadel Pharmaceuticals plc filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/avadel-pharmaceuticals-plc-filed-sec-form-8-k-other-events-6352991)
- 2026-01-12 21:09 UTC [SEC Form 8-K] [Avadel Pharmaceuticals plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/avadel-pharmaceuticals-plc-filed-sec-form-8-k-submission-of-matters-6346396)
- 2026-01-12 21:05 UTC [Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes](https://www.quantisnow.com/insight/avadel-pharmaceuticals-announces-that-avadel-shareholders-approve-the-proposed-acquisition-6346341)
- 2025-12-19 21:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Avadel Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-avadel-pharmaceuticals-plc-6323794)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AVDL
- RSS and alerts for AVDL: https://www.quantisnow.com/docs/rss-feeds.md